Innovative Medicine Backed by the Power of
BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.
Innovative Medicine
Backed by the
Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D Economics
- Shortens Development Timelines
- Increases Probability of Success
AI-based Drug Development
Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug identification and development
Neuroscience
Immuno-Oncology
Aug 09, 2022
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational HighlightsVIEW RELEASE
Aug 03, 2022
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth ConferenceVIEW RELEASE
Aug 01, 2022
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid WithdrawalVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Aug 16, 2022 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
14.87
CHANGE
-0.39 (-2.56%)
